Our Board of Directors & Advisors


Gerald Chan

Chief Executive Officer, Morningside Group

Dr. Gerald Chan co-founded Morningside, a diversified investment group engaged in private equity and venture capital investments in North America, Asia and Europe, in 1987. Morningside has been an active investor in China since 1992.

Dr. Chan is a director of publicly listed Hang Lung Group Limited, a Hong Kong-based property holding company. He serves on the boards of several biotechnology companies in North America and Europe including Stealth Peptides, Advanced Cell Diagnostics, Matrivax, Vaccine Technologies Inc., and Oxyrane. He is a member of the Global Advisory Council of the International Society for Stem Cell Research, the International Board of Governors of the New York Academy of Sciences, the Board of Trustees of Fudan University in Shanghai, the Global Advisory Council of Harvard University, and chairs the Board of Overseers of the Morningside College of the Chinese University of Hong Kong.

Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics, and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training in pathology at the Harvard Medical School and the Dana-Farber Cancer Institute.

Stephanie O'Brien

Partner, Morningside Group

Stephanie O'Brien represents Morningside Ventures and has extensive experience working with venture-backed technology companies.

She focuses on early-stage companies, working with CEOs on building the management team and developing business plans. She has served on numerous private company boards, including ViOptiox, Inc., I-Behavior, Inc., Natural Polymer International Corp., Serica Technology, Inc., Alacer Biomedical, Inc., Inimex Pharmaceuticals, Inc. and BiddingForGood, Inc.

She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, N.A, where she completed the loan officer credit training program and then worked in international portfolio analysis.

After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily with venture capital finance and start-up companies.

Deepak Malhotra

Professor, Harvard Business School

Deepak Malhotra is the Eli Goldston Professor of Business Administration at the Harvard Business School. His teaching, research and advisory work is focused on negotiation, deal-making and conflict resolution. Deepak has won numerous awards for his teaching, including the HBS Faculty Award by Harvard Business School's MBA Class of 2011, and the Charles M. Williams Award. In both 2011 and 2012, the MBA students selected Deepak to give the end-of-year speech to graduating students. In 2014, Deepak was chosen by Poets & Quants to be among their "40 under 40", a listing of the world's best business school professors under the age of 40.


Doug Williams

Chief Technology Officer, iSpecimen

Doug Williams is the chief technology officer of iSpecimen, a supplier of human clinical specimens to the research, therapeutic, and diagnostic industries. Previously, he served as the president and chief executive officer of Codiak Biosciences.

Doug held various leadership roles as senior vice president and vice president in the fields of technology and engineering at Pearson, Zipcar, Empirix, and NetManage. He also served as a director of Analogic and Data Translation.

Doug obtained his bachelor’s degree in electrical engineering and computer science from Princeton University and his MBA from Harvard Business School.